Combination / selection rationale: NK is activity-standardized while red yeast rice has separate active constituents; a capsule trial illustrates independent specification within one format.
Published evidence / source details: A 2024 trial analysed 178 participants over 90 days across blend, single-ingredient and placebo groups. Each blend capsule measured 610.3 FU NK and 1.5 mg monacolins; the combination group showed improvements in triglycerides, total cholesterol and diastolic pressure.
Development insights: Calculate NK loading from lot FU/g and red-yeast-rice actives separately. Recheck activity after processing; control monacolins, citrinin and market requirements, and compare activity retention with each partner.
Evidence scope: Evidence concerns a specified population and formula, not a treatment claim or general intake recommendation.
2024 · NK/RYR randomized study · DOI 10.3389/fnut.2024.1380727 ↗